2026 life sciences industry outlook
Key takeaways
What is the life sciences industry outlook?
The life sciences industry continues to evolve amid shifts in innovation, technology, regulation, capital markets and the broader economic environment. RSM’s industry outlook examines the trends shaping biopharma, medtech and life sciences services companies, with a focus on what they mean for middle market organizations as they navigate change, pursue growth and position themselves for what’s ahead.
TREND 1: Artificial intelligence readiness
As AI moves from an emerging technology to a business imperative, life sciences companies that lag in adoption may risk falling behind competitors, while those that pair AI capabilities with scientific expertise, high-quality data and regulatory readiness will be better positioned to create long-term competitive advantage.
TREND 2: Medtech innovation is shifting
As medtech innovation continues to shift, companies will need to be more deliberate in how they invest in, develop and bring new devices to market. Medtech companies should prioritize capital efficiency, portfolio focus and strategic trials rather than simply increasing R&D levels.
TREND 3: Clinical trial timelines in flux
As clinical trial timelines compress in the U.S. and lengthen in the UK, life sciences companies should proactively tailor trial design, geography and funding strategies to each market’s realities.